… (1 or 2 points), and 11.0% (95%CI: 8.8-13.8) in those with a high-risk Khorana score (3 …
high risk according to the Khorana score. In conclusion, the Khorana score can be used to select …

… In this metaanalysis, we focused on the Khorana score, because it is the most widely
studied and used risk-stratification tool. However, a substantial variation in VTE risk has been …

… At the same time, this analysis highlights the limited sensitivity of the Khorana score. That
is, although the risk is significantly elevated in cancer patients with a high Khorana score, the …

… Khorana score to predict high VTE risk in the ambulatory cancer patient receiving chemotherapy
[5]. The Khorana score … ] considered cancer patients with a score of two points or higher …

… and meta-analysis to provide high-level evidence on the performance of the Khorana score
… trials and cohort studies that evaluated the Khorana risk score in patients with cancer were …

… Khorana score patients and 6.4% among low-to-intermediate risk patients (OR 1.6; 95%-CI
1.1-2.2). The dichotomous Khorana score … cancer and a high-risk Khorana score (N=619), the …

… According to this meta-analysis, the Khorana score is suitable for cancer patients receiving
chemotherapy in a 3–6-month timeframe rather than “forever”. The incidence of PE in this …

… risk analyses. Using the guideline-recommended threshold of ≥2, the Khorana score did not
… In conclusion, the Khorana score was able to stratify ambulatory cancer patients according …

… The Khorana score (KS) clinical algorithm is used to predict VTE risk in cancer patients.
The study objective was to evaluate VTE and survival rates among patients newly diagnosed …

… all 270 patients to calculate Khorana score. Second, although the incidence detected was
consistent with that reported in other studies, 11 our analysis might be underpowered to detect …